NCT05263050 2025-12-03
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Recruiting
Clinical Trials
5 trialsNCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT05249114 2025-03-10
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
Phase 1 Active not recruiting
NCT05048901 2024-07-05
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
National Health Research Institutes, Taiwan
Phase 1/2 Recruiting
NCT04427787 2021-09-05
LOLA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown